Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. As part of its 5x15 strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in clinical development, including programs in advanced stages, on its own or with a partner by the end of 2015. Alnylam was founded by and incubated at Polaris.


In 2002, the decision to establish a company on therapeutic RNA interference technology was high risk. Paul Schimmel, a longstanding friend, suggested talking to Terry at Polaris and a very pleasant relationship began with the establishment of Alnylam. Ten years later, I consider myself part of the extended Polaris network of friends and entrepreneurs.

- Phil Sharp, Nobel Laureate, MIT Professor : Co-Founder, Alnylam

Contact Info

300 Third Avenue, Third Floor, Cambridge, MA, 02142
Tel: 617-551-8200

Polaris Lead

Alan Crane